- About Us
- Services & Solutions
- Technologies
- Discovery
- Reagent Materials Generation
- Monoclonal Antibody Discovery
- Bispecific & Multispecific Antibody Generation
- Lead Optimization
- In Vitro Lead Characterization
- In Vivo Lead Characterization
- Other Molecular Modalities
- IND Filing Support
- Protein Sciences
- Protein Production
- Protein Analytics
- Bioinformatics
- Protein Sciences
- Mammalian
- Microbial
- mRNA
- Viral Vaccines
- WuXi XDC – Bioconjugation
- Testing
- Sustainability
- Careers
- Investors
- News & Resources
WuXi Biologics
Offering End-to-End Solutions
- About Us
About Us - Services & SolutionsAbout Us
- SustainabilityAbout Us
- CareersAbout Us
- InvestorsAbout Us
- News & ResourcesAbout Us
Scientific Poster Download
ECI 2023
Further Accelerating Cell Line Development and Reducing CMC Timeline to 3 Months from DNA to IND: the Journey from COVID to Non-COVID Programs
Sam Zhang, Kee Wee Tan, Junghao Wang, Weichang Zhou
WuXi Biologics, Waigaoqiao Free Trade Zone, Shanghai, China
| Since the COVID-19 outbreak, unconventional cell line development (CLD) strategies have been employed to enable development of SARS-CoV-2-neutralizing antibodies at expedited speed. In this work, we summarize the accelerated development of a total of seven antibody programs, some of which have received emergency use authorization (EUA) approval in less than two years. |  |
Notice:
You are leaving WuXi Biologics Website, after which our Privacy Notice will not apply. Please keep it in mind the protection of your privacy. Are you willing to proceed?